Inventisbio
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Clive Hills Rd, Short Hills, New Jerse...Phone Number
(908) 370-5826Website
www.inventisbio.comRevenue
$13.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Inventisbio
益方生物科技（上海）股份有限公司 focuses on the development of innovative drugs for major diseases, particularly in the fields of tumor autoimmune diseases and metabolic disorders. The company has successfully launched two innovative drugs and has three candidate drugs currently in clinical trials, with two core products undergoing phase III clinical trials. They are committed to advancing drug development targeting synthetic lethal pathways, autoimmune targets, kinases, and tumor driver genes. Their pipeline includes a range of preclinical candidate compounds across multiple therapeutic areas.Explore more
Popular SearchesInventisBio LLCInventisBio Co LtdInventisBioInventisBio Inc益方生物 InventisBioSIC Code 28,283NAICS Code 32,325Show moreInventisbio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inventisbio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Inventisbio recently announced quarterly report
Product Launch: Get notified when Inventisbio launches new products
Click to see if Inventisbio had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Inventisbio
Website visits: Recent activity has been detected on your website
Check if Inventisbio has recently received funding, and reach out quickly before it becomes old news!
Check out if Inventisbio is spiking on competitors!
Inventisbio, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Inventisbio has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Inventisbio
Compare insights from companies similar to Inventisbio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Inventisbio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inventisbio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inventisbio.
Inventisbio financials insights
Gather financial insights about Inventisbio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$11M
2017
Series B
$19M
2019
Series C
$70M
2020
Series D
$147M
Inventisbio Tech Stack
A closer look at the technologies used by Inventisbio
See more technologies
Inventisbio News & Media
InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis
– D-2570 demonstrates robust efficacy and favorable safety profile, achieving skin clearance comparable to leading biologics – SHANGHAI, Dec. 3, 2024 /PRNewswire/ -- InventisBio Co., Ltd. today announced promising results from a Phase 2 clinical trial of D-2570, an oral selective inhibitor of the TYK2 kinase, in patients with moderate to severe plaque psoriasis. The randomized, multicenter, double-blind, placebo-controlled study demonstrated that D-2570 achieved significant efficacy in improvingQiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price...InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients
SHANGHAI, April 11, 2022 /PRNewswire/ -- InventisBio Co., Ltd., a clinical-stage biotech company based in Shanghai, China has published the clinical data of their oral KRAS G12C inhibitor D-1553, for the first time in cancer patients. These data are presented in two e-posters at the...Investors Prove Confidence in InventisBio with $147 Million
Starting with just $11 million seed in 2015, investors have proven their faith in InvestiBio with their increasing financial support.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Inventisbio
Sign Up For FreeTo access detailed company insights
益方生物科技（上海）股份有限公司 focuses on the development of innovative drugs for major diseases, particularly in the fields of tumor autoimmune diseases and metabolic disorders. The company has successfully launched two innovative drugs and has three candidate drugs currently in clinical trials, with two core products undergoing phase III clinical trials. They... Read More
